Amylyx Pharmaceuticals, Inc.（AMLX）股票分析AMLXAmylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amylyx Pharmaceuticals Inc is currently not a strong buy due to its recent price decline and negative financial performance, despite a promising future with a current price of $26.34 and a forward P/E of 2.77. The stock has dropped 6.40% over the last five days and insiders have increased selling by 2291.45%, indicating potential caution. However, analyst targets suggest significant upside, with Guggenheim raising their target to $57, which reflects a potential increase of over 116% from the current price. The main risk is the company’s ongoing negative net income, which was -43,423,000 in Q2 2026, highlighting financial instability that could affect future performance.